14222-60-7 Usage
Description
Protionamide, a yellow solid, is a potent pharmaceutical compound with significant antibacterial properties. It is primarily recognized for its effectiveness against Mycobacterium tuberculosis bacteria, making it a crucial component in the fight against tuberculosis. Additionally, it has demonstrated utility in treating leprosy, further highlighting its importance in combating various bacterial infections.
Uses
Used in Pharmaceutical Industry:
Protionamide is used as an anti-tuberculosis agent for its ability to target and neutralize Mycobacterium tuberculosis bacteria, which is responsible for causing tuberculosis. Its tuberculostatic properties make it a valuable asset in the treatment and management of this infectious disease.
Used in Leprosy Treatment:
In addition to its role in tuberculosis treatment, Protionamide is also utilized as an antibacterial agent in the treatment of leprosy. Its effectiveness against Mycobacterium leprae, the bacterium that causes leprosy, contributes to its importance in the management and treatment of this chronic disease.
Overall, Protionamide's versatility in addressing different bacterial infections, particularly those caused by Mycobacterium species, underscores its significance in the pharmaceutical industry and its potential for further research and development in combating various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 14222-60-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,2,2 and 2 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 14222-60:
(7*1)+(6*4)+(5*2)+(4*2)+(3*2)+(2*6)+(1*0)=67
67 % 10 = 7
So 14222-60-7 is a valid CAS Registry Number.
InChI:InChI=1/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12)
14222-60-7Relevant articles and documents
Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in Mycobacterium tuberculosis
Prieri, Marion,Frita, Rosangela,Probst, Nicolas,Sournia-Saquet, Alix,Bourotte, Marilyne,Déprez, Benoit,Baulard, Alain R.,Willand, Nicolas
, p. 35 - 46 (2018/10/02)
Ethionamide is a key antibiotic prodrug of the second-line chemotherapy regimen to treat tuberculosis. It targets the biosynthesis of mycolic acids thanks to a mycobacterial bioactivation carried out by the Baeyer-Villiger monooxygenase EthA, under the control of a transcriptional repressor called EthR. Recently, the drug-like molecule SMARt-420, which triggers a new transcriptional regulator called EthR2, allowed the derepression a cryptic alternative bioactivation pathway of ethionamide. In order to study the bioactivation of a collection of thioisonicotinamides through the two bioactivation pathways, we developed a new two-step chemical pathway that led to the efficient synthesis of eighteen ethionamide analogues. Measurements of the antimycobacterial activity of these derivatives, used alone and in combination with boosters BDM41906 or SMARt-420, suggest that the two different bioactivation pathways proceed via the same mechanism, which implies the formation of similar metabolites. In addition, an electrochemical study of the aliphatic thioisonicotinamide analogues was undertaken to see whether their oxidation potential correlates with their antitubercular activity measured in the presence or in the absence of the two boosters.
